Code

• As a cGMP compliant facility, Perspective intends to utilize the facility to manufacture clinical supply of high quality 203Pb-labeled tumor-specific peptides to visualize and diagnose tumors, and 212Pb-labeled radiopharmaceuticals to treat target tumors with targeted alpha therapies (TAT).
• The facility acquisition is part of a series of strategic agreements with Lantheus that Perspective announced on January 9, 2024, which included an initial equity investment in Perspective.
• “We look forward to welcoming the exceptional talent at this facility and integrating them into our team,” said Shane Cobb, Executive Vice President of Operations, Perspective Therapeutics.
• This is a significant milestone for Perspective as we build upon the progress we have made in establishing clinical manufacturing.”
  “We are thrilled to expand our manufacturing and supply chain infrastructure to include this facility capable of operating in compliance with Parts 212 and 211,” said Thijs Spoor, Chief Executive Officer, Perspective Therapeutics.

• Shareholders should not draw any conclusions about a Fund’s investment performance from the amount of the Fund’s current distributions or from the terms of the Fund’s Plan.
• BlackRock Enhanced Government Fund, Inc. (NYSE: EGF), BlackRock Debt Strategies Fund, Inc. (NYSE: DSU), BlackRock Floating Rate Income Strategies Fund, Inc. (NYSE: FRA), BlackRock Floating Rate Income Trust (NYSE: BGT), BlackRock Corporate High Yield Fund, Inc. (NYSE: HYT), BlackRock Credit Allocation Income Trust (NYSE: BTZ), BlackRock Limited Duration Income Trust (NYSE: BLW), BlackRock Core Bond Trust (NYSE: BHK), BlackRock Multi-Sector Income Trust (NYSE: BIT), BlackRock Income Trust, Inc. (NYSE: BKT) and BlackRock Taxable Municipal Bond Trust (NYSE: BBN) have adopted a Plan to support a level monthly distribution of income, capital gains and/or return of capital.
• The fixed amounts distributed per share are subject to change at the discretion of each Fund’s Board of Directors/Trustees.
• Each Fund’s estimated sources of the distributions paid as of February 29, 2024 and for its current fiscal year are as follows:
  Estimated Allocations as of February 29, 2024

• TRU Simulation announced today a new, cutting-edge Veris™ Virtual Reality (VR) Flight Simulator that provides helicopter and fixed-wing model customers with a more cost-effective and innovative solution to accomplish pilot training.
• The Veris offers the benefits of a full flight simulator experience in a compact, cost-effective and pioneering design," said Jerry Messaris, vice president and general manager, TRU Simulation.
• The Veris VR Flight Simulator is designed to meet both FAA flight training device level 7 and EASA flight training device level 3 standards.
• The Veris offers state-of-the-art simulator components, including:
  TRU Simulation is an industry leader in developing advanced, high-fidelity full flight simulators and flight training devices.

The Information Commissioner’s Office (ICO) has ordered a charity to stop sending unsolicited marketing texts to people without their consent, as it reminds all charities of their legal obligations.